• Explore /
  • Poster
  • / A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with CAPRIN-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with CAPRIN-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Abstract Poster

Authors

Ronan Kelly

Ronan Joseph Kelly

Charles A. Sammons Cancer Center, Baylor University Medical Center at Dallas, Dallas, TX

Ronan Joseph Kelly , Sun Young Rha , Jeeyun Lee , Fumiyoshi Okano , Kohei Shitara

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Small Bowel Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT06038578

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr TPS420)

DOI

10.1200/JCO.2024.42.3_suppl.TPS420

Abstract #

TPS420

Poster Bd #

N5

Abstract Disclosures

Similar Posters

First Author: Ronan Joseph Kelly

First Author: Timothy Jay Price

First Author: Yelena Y. Janjigian

First Author: Kohei Shitara